Amphastar Pharmaceuticals

{{Short description|American pharmaceutical company}}

{{infobox company

| name = Amphastar Pharmaceuticals, Inc.

| logo = Amphastar Pharmaceuticals logo.svg

| type = Public

| traded_as = {{ubl|class=nowrap|{{NASDAQ|AMPH}}|S&P 600 component}}

| location = Rancho Cucamonga, California, United States

| key_people = {{ubl|class=nowrap

| Mary Z. Luo | {{small|(Chairman of the Board)}}

| Jack Yongfeng Zhang | {{small|(CEO)}}}}

| revenue = {{nowrap|{{increase}} US$ 644.4 million {{small|(2023)}}}}

| operating_income = {{nowrap|{{increase}} US$ 196.9 million {{small|(2023)}}}}

| net_income = {{nowrap|{{increase}} US$ 137.5 million {{small|(2023)}}}}

| assets = {{nowrap|{{increase}} US$ 741.9 million {{small|(2022)}}}}

| equity = {{nowrap|{{increase}} US$ 528.6 million {{small|(2022)}}}}

| num_employees = 1,615

| homepage = {{url|https://www.amphastar.com/|Amphastar.com}}

| footnotes = {{cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1297184/000129718423000019/amph-20221231x10k.htm|title=U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc.|publisher=U.S. Securities and Exchange Commission|accessdate=July 31, 2023}}{{Cite web |title=Amphastar Pharmaceuticals Inc |url=https://www.bloomberg.com/quote/AMPH:US |access-date=2024-03-19 |website=Bloomberg}}{{Cite web |title=Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement - Yahoo Finance |url=https://finance.yahoo.com/quote/AMPH/financials/ |access-date=2024-03-19 |website=finance.yahoo.com |language=en-US}}

}}

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.{{cite web|title=Amphastar Pharmaceuticals, Inc. (AMPH)|url=http://www.nasdaq.com/symbol/amph|website=NASDAQ.com|publisher=NASDAQ OMX Group|accessdate=3 January 2016}} It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.{{cite web|url=https://www.reuters.com/finance/stocks/companyProfile/AMPH.O|title=Profile:Amphastar Pharmaceuticals Inc (AMPH.O)|publisher=Reuters}}

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.{{cite news|last1=Arsalan|first1=Arif|title=After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version|url=https://endpts.com/after-steering-through-a-controversy-over-opioid-drug-price-fda-rejects-amphastars-intranasal-version/|work=Endpoints|date=February 21, 2017}} In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.{{Cite web |last=Raymond |first=Nate |date=June 19, 2019 |title=Momenta, Amphastar settle generic Lovenox drug patent case |url=https://www.reuters.com/article/idUSL2N23Q1VK/ |url-status= |access-date=March 14, 2024 |website=Reuters}}

In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.{{Cite web |title=Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash |url=https://finance.yahoo.com/news/eli-lilly-divests-low-blood-142544130.html |access-date=2023-04-26 |website=Yahoo Finance |date=24 April 2023 |language=en-US}}{{Cite web |title=Amphastar buys Baqsimi to build out specialty med offering |url=https://www.thepharmaletter.com/article/amphastar-buys-baqsimi-to-build-out-specialty-med-offering |access-date=2023-04-26 |website=www.thepharmaletter.com}}